| ［1］ |
Chng WQ, Yew YW. Nail manifestations in atopic dermatitis: a systematic review［J］. Int J Dermatol, 2020,59（6）:670⁃676. doi: 10.1111/ijd.14726.
|
| ［2］ |
Hur K, Han B, Lim SS, et al. Histopathologic findings of idiopathic trachyonychia: an analysis of 30 adult patients［J］. J Cutan Pathol, 2021,48（3）:396⁃402. doi: 10.1111/cup.13909.
|
| ［3］ |
Clark A, Jellinek NJ. Intralesional injection for inflammatory nail diseases［J］. Dermatol Surg, 2016,42（2）:257⁃260. doi: 10.1097/DSS.0000000000000621.
|
| ［4］ |
Merola JF, Elewski B, Tatulych S, et al. Efficacy of tofacitinib for the treatment of nail psoriasis: two 52⁃week, randomized, controlled phase 3 studies in patients with moderate⁃to⁃severe plaque psoriasis［J］. J Am Acad Dermatol, 2017,77（1）:79⁃87.e1. doi: 10.1016/j.jaad.2017.01.053.
|
| ［5］ |
Chelidze K, Lipner SR. Nail changes in alopecia areata: an update and review［J］. Int J Dermatol, 2018,57（7）:776⁃783. doi: 10.1111/ijd.13866.
|
| ［6］ |
Dube V, Bhushan R. Tofacitinib for the treatment of twenty⁃nail dystrophy: a single case report［J］. Indian J Dermatol, 2022,67（6）:725⁃727. doi: 10.4103/ijd.ijd_492_22.
|
| ［7］ |
Iorizzo M, Haneke E. Tofacitinib as treatment for nail lichen planus associated with alopecia universalis［J］. JAMA Dermatol, 2021,157（3）:352⁃353. doi: 10.1001/jamadermatol.2020.4555.
|
| ［8］ |
Bauman JN, Doran AC, King⁃Ahmad A, et al. The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective Janus kinase inhibitor, in humans［J］. Drug Metab Dispos, 2022,50（8）:1106⁃1118. doi: 10.1124/dmd. 122.000829.
|
| ［9］ |
Lugović⁃Mihić L, Meštrović⁃Štefekov J, Potočnjak I, et al. Atopic dermatitis: disease features, therapeutic options, and a multidisciplinary approach［J］. Life （Basel）, 2023,13（6）:1419. doi: 10.3390/life13061419.
|
| ［10］ |
Tominaga M, Takamori K. Peripheral itch sensitization in atopic dermatitis［J］. Allergol Int, 2022, 71（3）:265⁃277. doi: 10.1016/j.alit.2022.04.003.
|
